Annovis Bio, Inc. (NYSE:ANVS – Get Rating) was up 7.5% during trading on Thursday . The stock traded as high as $11.00 and last traded at $10.88. Approximately 21,838 shares were traded during mid-day trading, a decline of 62% from the average daily volume of 56,957 shares. The stock had previously closed at $10.12.
Separately, LADENBURG THALM/SH SH started coverage on Annovis Bio in a research note on Monday, May 2nd. They issued a “buy” rating for the company.
The company has a market capitalization of $88.82 million, a P/E ratio of -5.04 and a beta of 2.12. The company’s 50-day moving average is $10.47 and its two-hundred day moving average is $13.74.
Several large investors have recently modified their holdings of ANVS. Essex LLC increased its holdings in shares of Annovis Bio by 9.4% in the 1st quarter. Essex LLC now owns 11,593 shares of the company’s stock worth $155,000 after buying an additional 1,000 shares during the last quarter. Sterling Investment Advisors Ltd. grew its holdings in shares of Annovis Bio by 31.1% during the 1st quarter. Sterling Investment Advisors Ltd. now owns 18,974 shares of the company’s stock valued at $253,000 after purchasing an additional 4,500 shares during the last quarter. Renaissance Technologies LLC grew its holdings in shares of Annovis Bio by 120.9% during the 1st quarter. Renaissance Technologies LLC now owns 23,197 shares of the company’s stock valued at $310,000 after purchasing an additional 12,697 shares during the last quarter. Two Sigma Advisers LP grew its holdings in shares of Annovis Bio by 906.7% during the 3rd quarter. Two Sigma Advisers LP now owns 30,200 shares of the company’s stock valued at $959,000 after purchasing an additional 27,200 shares during the last quarter. Finally, Geode Capital Management LLC grew its holdings in shares of Annovis Bio by 6.2% during the 3rd quarter. Geode Capital Management LLC now owns 40,945 shares of the company’s stock valued at $1,300,000 after purchasing an additional 2,376 shares during the last quarter. 13.68% of the stock is currently owned by hedge funds and other institutional investors.
About Annovis Bio (NYSE:ANVS)
Annovis Bio, Inc, a clinical stage drug platform company, develops drugs to treat neurodegeneration. The company's lead compound is Buntanetap, an orally administered drug, which has completed Phase 2a clinical trials for the treatment of Alzheimer's disease (AD) and Parkinson's disease, as well as is in clinical trials for Alzheimer's disease in Down Syndrome and other chronic neurodegenerative disorders.
- Get a free copy of the StockNews.com research report on Annovis Bio (ANVS)
- It’s A Comfortable Time To Buy Steelcase
- Worthington Posts Strong Results, But Earnings Fall On One-Off Adjustments
- A Tasty Entry Point Into Darden Restaurants International
- NXP Semiconductors: Strong Earnings & New Microcontrollers for Electric Vehicles
- Lithium Stocks Are Offering Unprecedented Opportunity To Investors
Receive News & Ratings for Annovis Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Annovis Bio and related companies with MarketBeat.com's FREE daily email newsletter.